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Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study
was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to
December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients
presented with poor performance status (ECOG X2); 46% of patients were categorised as high intermediate or high-risk group
according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell
lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60%
CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1–99.0) in
patients with localised disease who had achieved a CR (range 29.6–165.7), three patients (50.0%) developed disease recurrence at
6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival
were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell
lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an
innovative therapy is urgently needed to improve survival in these patients.
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Extranodal NK/T cell lymphoma is subcategorised into nasal and
nasal-type NK/T cell lymphomas according to the major sites of
anatomic involvement (Jaffe et al, 1996, 1999). The nasal NK/T cell
lymphoma commonly presents with midline facial destructive
disease, shows a strong association with Epstein–Barr virus (EBV),
and occurs prototypically within the nasal cavity (Liang et al, 1995;
Jaffe, 1996; Jaffe et al, 1996; Hirakawa et al, 1999; Cheung et al,
2002). It was previously categorised as angiocentric lymphoma in
the Revised European-American Lymphoma (REAL) classification,
and has been recently recategorised as extranodal NK/T cell
lymphoma in the new WHO classification of lymphoid neoplasms
(Harris et al, 1994; Jaffe, 1996; Jaffe et al, 1996; Harris et al, 1999).
In limited cases, NK/T cell lymphoma may predominantly occur
in extranasal sites without involvement of nasal cavity or
nasopharynx. It is not until recently that this form of extranodal
lymphoma has been recognised to present with highly aggressive
clinical course and share similar immunophenotypic profile with
nasal NK/T cell lymphoma (Kern et al, 1992; Wong et al, 1992).
This disease entity was recognised as an independent form of
disease and defined as nasal-type NK/T cell lymphoma in Hong
Kong workshop in 1994 (Jaffe, 1996). The largest series on nasal-
type NK/T cell lymphoma reported a retrospective review of 34
cases and observed that these patients were often refractory to
combined chemotherapy (Chan et al, 1997). As most published
reports on NK/T cell lymphomas mainly focus on the clinico-
pathologic features, the role of chemotherapy on the clinical
outcome as well the optimal treatment approach needs to be
defined. None of the previous studies analysed the treatment
outcome of primary chemotherapy in nasal-type NK/T cell
lymphoma.
As nasal-type NK/T cell lymphoma is known to be one of the
most aggressive lymphomas, it is imperative to offer an appro-
priately aggressive treatment at an early stage of disease. We report
the clinical features and treatment outcome of nasal-type NK/T
cell lymphoma patients, especially after anthracycline-based
chemotherapy.
PATIENTS AND METHODS
In total, 26 patients, who were diagnosed as nasal-type NK/T cell
lymphoma between January 1991 to December 2003, were included
in the analysis. All patients were histologically confirmed of NK/T
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scell lymphoma, according to WHO classification and had proven
NK/T cell type by immunohistochemistry, flow cytometry, or EBV
in situ hybridisation. Nasal NK/T cell lymphoma, blastic NK-cell
leukaemia, aggressive NK cell lymphoma/leukaemia, and peri-
pheral T cell lymphoma, unspecified were excluded from the
analysis. Nasal NK/T cell lymphoma was defined as lymphomas
occurring within nasal cavity and/or upper aerodigestive tract such
as oral cavity, palate, larynx, pharynx, and tonsil. Nasal-type NK/T
cell lymphoma was defined as those primarily involving outside
nasal cavity/nasopharynx or upper aerodigestive tract. Patients
with lesions within the nasal cavity and secondary spread to other
organs were categorised as nasal NK/T cell lymphoma and were
excluded from the analysis. The pathologic diagnosis of nasal-type
NK/T cell lymphoma was based on the following criteria:
expression of cytoplasmic CD3 and CD56 and positivity for EBV
in situ hybridisation. If EBV in situ hybridisation was negative, the
immunophenotype studies should demonstrate cytoplasmic CD3
expression and positive cytotoxic molecules such as TIA-1.
The following clinical data were collected from the record:
patient demographics, complete blood count, lactic dehydrogenase
(LDH) level, Ann Arbor stage, IPI, bone marrow findings, the
presence of B symptoms, performance status, date of diagnosis,
type of treatment, treatment response, date of relapse, date of last
follow-up, live status, and cause of death.
Histology
In all cases, haematoxylin–eosin-stained slides were reviewed by
two pathologists. Immunophenotyping was performed using a
panel of monoclonal antibodies including antibodies against
cytoplasmic CD3 (Dakopatts, Copenhagen, Denmark), CD20
(Dakopatts), CD56 (Monosan, Uden, the Netherlands), and TIA-1
(Coulter, Hialeah, FL, USA). EBV RNA was detected by an in situ
hybridisation technique. Briefly, paraffin sections were pretreated
with xylene, followed by treatment with proteinases K and
hybridised with FITC-conjugated EBV oligonuecleotides (Dako-
patts) complementary to the nuclear RNA portion of the EBER 1
and 2 genes.
Treatment
The anthracycline-based chemotherapy regimen used were as
following: CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisolone), dose-escalated CHOP(deCHOP), COPBLAM (cyclo-
phosphamide, vincristine, prednisone, bleomycin, doxorubicin,
procarbazine), and EPOCH (etoposide, doxorubicin, vincristine,
cyclophosphamide, prednisolone). The nonanthracycline-based
chemotherapy regimens were DICE (dexamethasone, ifosfamide,
cisplatin, etoposide) and CVP (cyclophosphamide, vincristine,
prednisone). CHOP regimen consisted of cyclophosphamide
(750mgm
 2 given intravenously on day 1), doxorubicin
(50mgm
 2 given intravenously on day 1), vincristine (1.4mgm
 2
but not more than 2.0mg given intravenously on day 1), and
prednisolone (100mg daily, given orally on days 1–5). Dose-
escalated CHOP consisted of cyclophosphamide(1250mgm
 2
given intravenously on day 1), doxorubicin (75mgm
 2 given
intravenously on day 1), vincristine (1.4mgm
 2 but not more than
2.0mg given intravenously on day 1), and prednisolone (100mg
daily, given orally on days 1–5) with G-CSF support until
neutrophil count recovery. The chemotherapy cycles were repeated
at 21-day intervals. The alternative regimens were COPBLAM
(cyclophosphamide 400mgm
 2, vincristine 1.0mgm
 2, and dox-
orubicin 50mgm
 2 intravenously on day 1, bleomycin 15mg
intravenously on day 14, procarbazine 100mgm
 2 and predniso-
lone 40mgm
 2 daily, given orally on days 1710); and EPOCH
(etoposide 50mgm
 2, vincristine 0.4mgm
 2, and doxorubicin
10mgm
 2, all given in a continuous infusion on days 1–4 with
cyclophosphamide 750mgm
 2 i.v. bolus on day 6 and oral
prednisone 60mgm
 2 on days 1–6). DICE regimen consisted of
dexamethasone 10mg q.i.d., ifosfamide 1gm
 2, cisplatin
25mgm
 2, etoposide 100mgm
 2, and mesna uroprotection
daily  4 given every 28 days, and CVP was cyclophosphamide
1000mgm
 2 i.v. on day 1, vincristine 1.4mgm
 2 (max. 2mg) i.v.
on day 1, and prednisolone 100mg daily, given orally on days 1–5.
In patients with localised disease, involved-field radiotherapy
(IFRT) was given at physician’s discretion following chemother-
apy. IFRT began 3 weeks after the completion of planned
chemotherapy. The total radiotherapy dose was 45Gy adminis-
tered over 5 weeks by conventional fractionation schedule (1.8Gy/
fraction, 5 fractions/week) to the prechemotherapy gross disease
extent.
Response criteria
The treatment response was assessed according to standard
response criteria (Cheson et al, 1999). Complete remission (CR)
was defined as no evidence of residual disease; partial response
(PR) was at least a 50% reduction in the tumour burden from the
onset of treatment; no response was less than 50% reduction in
tumour burden or disease progression. CR/unconfirmed (Cru) was
defined as the reduction of mass by more than 75% with no newly
developed lesions. Assessment of response was evaluated by
follow-up clinical, radiologic, and laboratory studies as determined
relevant by the clinician.
Statistical analysis
Survival rates were compared for statistical differences by using
log-rank analysis. P-values less than 0.05 were considered
statistically significant and all P-values correspond to two-sided
significance tests. Overall survival (OS) and disease-free survival
(DFS) were estimated using the Kaplan–Meier product-limit
method. Disease-free survival was calculated from the date
treatment began to the date when the disease progression was
recognised or the date of the last follow-up visit. Overall survival
was measured from the date of diagnosis to the date of death or the
last follow-up visit.
RESULTS
Clinical characteristics and OS
The clinical characteristics of patients with nasal-type NK/T cell
lymphoma are listed in Table 1. The median age at diagnosis was
50 years (range, 22–81 years). There was a male preponderance
with a male to female ratio of 2.3:1. One half of patients presented
with poor performance status (ECOG X2), 46% of patients were
categorised as high intermediate or high-risk group according to
IPI, and 46% of patients were diagnosed at advanced stage. B
symptoms occurred in 11 (42.3%) patients. An OS curve is shown
in Figure 1 for all patients (n¼26). The median survival for
patients with nasal-type NK/T cell lymphoma was 7.4 months (95%
CI, 0.1, 16.9). The median follow-up duration for living patients
was 53.4 months with a range of 29.6–99.0 months. The major sites
of involvement were as following: gastrointestinal tract (n¼8),
cutaneous (n¼7), soft tissues (n¼8), pleura (n¼1), and liver
(n¼2) (Table 2).
Localised nasal-type NK/T cell lymphoma
Of 14 patients with early stage nasal-type NK/T cell lymphoma
(stage I and II), 10 patients received primary anthracycline-based
chemotherapy (nine CHOP, one COPBLAM). Two patients under-
went primary surgical resection due to their initial presentation of
bowel obstruction and received CHOP chemotherapy as post-
operative treatment. One patient presented with soft tissue mass at
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scalf and achieved CR following mass excision and IFRT but
experienced local relapse. One remaining patient had best
supportive care due to old age and patient’s refusal for further
treatment. Of 10 patients who received anthracycline-based
chemotherapy with or without IFRT as a primary treatment, six
patients (60.0%) achieved CR. After a median follow-up of 24.4
months of these patients (range 3.1–99.0), three patients (50.0%)
developed disease recurrence at 6.1, 21.8, and 52.1 months,
respectively. The patterns of recurrence were locoregional in all
three patients. Three patients, who achieved CR after CHOP
chemotherapy followed by IFRT, remain alive in remission at 29.6,
30.5, and 99.0 months, respectively. Of five patients who were
refractory to the initial anthracycline-based chemotherapy, two
patients died after two and six cycles of CHOP chemotherapy,
respectively, and three patients received salvage treatment with
either high-dose cytarabine or ifosfamide-based chemotherapy. All
of the five anthracycline-refractory patients died between 3.1 and
72.8 months.
Table 1 Patient characteristics
Patients
No. %
Median age (years), range 50 (22–81)
Sex (M:F) 18:8
Performance status (ECOGX2) 13 50.0
B symptom (+) 11 42.3
Stage I, II 14 53.9
IPI
Low 7 26.9
Low intermediate 7 26.9
High intermediate 6 23.1
High 6 23.1
LDH (high) 16 61.5
EBV ISH (+) 18/23 78.3
BM involvement 2 7.7
Time (months)
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0.0
Median OS: 7.4 months (95% CI, 0.1, 16.9) 
Figure 1 Overall survival according to subtypes.
Table 2 Treatment outcome
No. Major site Stage
Initial
treatment
Treatment
response Status
F/U
(months) Pattern of failure/remark
1 Colon Localised CHOP PR DOD 6.7
2 Terminal ileum Localised Surgery-CHOP PD DOD 3.1
3 Colon Disseminated Surgery N/A DOD 0.9
4 Duodenum Disseminated CHOP PD DOD 35.4
5 Ileum Disseminated EPOCH PD DOD 0.6
6 Ileum Localised Surgery-CHOP CR DOO 52.9
7 Stomach, spleen Disseminated CHOP PD DOD 1.3
8 Skin, leg Disseminated Supportive care N/A DOD 0.4
9 Skin, foot Localised deCHOP-RT CR AIR 30.5 No relapse
10 Skin, elbow Disseminated Supportive care N/A DOD 24.9
11 Skin, eyelid Disseminated CVP PD DOD 0.3
12 Skin, eyelid Localised COPBLAM PD DOD 72.8
13 Skin, eyelid Localised DeCHOP-RT CR AIR 29.6 No relapse
14 Skin, hand Localised CHOP CR DOD 18.5 Systemic relapse
15 Soft tissue, inguinal LN Localised CHOP-RT CR DOD 36.4 Locoregional relapse-salvage
chemo-DOD
16 Jejunum, cervical LNs Disseminated CHOP PD DOD 7.4
17 Liver, porta hepatic LNs Disseminated CHOP PD DOD 2.8
18 Muscle, submental LN Localised CHOP PD DOD 5.6
19 Soft tissue, calf Localised RT CR AWD 76.3 Locoregional relapse-RT-PD-
salvage chemo-AWD
20 Muscle, masseter Localised CHOP PD DOD 13.2
21 Soft tissue, elbow Localised CHOP-RT CR AIR 99.0 No relapse
22 Soft tissue, thigh Localised Supportive care N/A DOD 13.0
23 Soft tissue, arm Disseminated DICE PD DOD 4.3
24 Soft tissue, hand Localised CHOP CR DOD 19.2 Locoregional relapse-salvage
chemo-DOD
25 Liver, spleen Disseminated CHOP PD DOD 4.2
26 Pleura, lung Disseminated CHOP PD DOD 1.1
DOD¼dead of disease; DOO¼dead of other cause; AIR¼alive in remission; AWD¼alive with disease; CHOP¼cyclophosphamide, doxorubicin, vincristine, prednisolone;
dose-escalated CHOP¼deCHOP; COPBLAM¼cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine; EPOCH¼etoposide, doxorubicin,
vincristine, cyclophosphamide, prednisolone; DICE¼dexamethasone, ifosfamide, cisplatin, etoposide; CVP¼cyclophosphamide, vincristine, prednisone.
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sDisseminated nasal-type NK/T cell lymphoma
In total, 12 patients (46.2%) presented with disseminated disease
and seven patients received primary anthracycline-based chemo-
therapy (six CHOP, one EPOCH). All seven patients developed
progressive disease despite of chemotherapy and died of disease.
Of these seven patients, only two patients (28.6%) have tolerated
more than two cycles of chemotherapy, while four patients (57.1%)
died after one cycle of chemotherapy. Of the remaining five
patients, two patients received nonanthracycline based chemother-
apy (DICE and CVP) and three patients did not receive
chemotherapy. Of 12 patients with disseminated disease, six
patients (85.7%) died of disease progression or treatment related
complications within less than 7 months from the date of
diagnosis.
Clinical predictors of survival
The important clinical factors predicting reduced survival were age
greater than 60, poor performance, presence of B symptoms, high
IPI score, advanced stage, and bone marrow involvement at
univariate level (Table 3, Figure 2). In stepwise Cox multivariate
regression analysis, age greater than 60, advanced stage, and poor
performance had an independent influence on poor survival.
DISCUSSION
As nasal-type NK/T cell lymphoma has recently been recognised as
an independent disease entity, neither the clinical features nor the
optimal therapeutic approach has been defined yet. This report is
the first paper to describe clinical behaviour and the treatment
outcome exclusively in patients with nasal-type NK/T cell
lymphoma. We analysed the treatment outcome of anthra-
cycline-based chemotherapy (CHOP in 15 out of 17 patients,
88.2%) in this rare subtype of lymphoma.
Nasal-type NK/T cell lymphoma has been introduced at the
Hong Kong workshop held in 1994 (Jaffe et al, 1996). This disease
entity encompasses all NK/T cell lymphomas occurring outside
nasal cavity and nasopharynx and is notorious for its aggressive
clinical course. The definition of nasal-type is confusing, which
resulted in different categorisation by various institutions (Kern
et al, 1992; Wong et al, 1992; Peiper, 1993; Nakamura et al, 1995;
Jaffe et al, 1996, 1999; Kobashi et al, 1996; Chan et al, 1997;
Bekkenk et al, 2004; Ko et al, 2004). We defined nasal-type
lymphoma as lesions primarily involving skin, soft tissues, visceral
organs such as liver, spleen, and gastrointestinal tract without any
lesions within the nasal cavity and/or upper aerodigestive tract
such as oral cavity, tonsil, pharynx, and larynx.
Several studies have reviewed small series of patients and
suggested an early administration of highly aggressive treatment
for nasal-type NK/T cell lymphoma. Chan et al (1997) summarised
32 cases of nasal-type NK/T cell lymphoma and described the
aggressive clinical course of the disease. Although survival data or
detailed treatment outcome were not provided, they found the
disease to be refractory to combination chemotherapy since 24
patients died in 1 week to 3 years, with a median of 3.5 months
despite of chemotherapy. Mraz-Gernhard et al (2001) reported 30
cases of nasal-type NK/T cell lymphomas with cutaneous
presentation and primary anthracycline-based chemotherapy was
administered in 10 patients, where five patients achieved CR with
short duration of response ranging from 1.5 to 4 months. A small
retrospective review on the treatment outcome of the first-line
anthracycline-based chemotherapy in extranodal NK/T cell
lymphoma reported a low CR rate of 28.6% in 14 cases of nasal-
type NK/T cell lymphoma patients (Kim et al, 2003). The Dutch
group recently analysed 38 nasal-type NK/T cell lymphoma
patients from the literature, of whom 70% received CHOP-like
chemotherapy and showed a median survival of 6 months
(Bekkenk et al, 2004). This group concluded that doxorubicin-
based chemotherapy was insufficient for effective disease control
for both nasal and nasal-type NK/T cell lymphomas.
Likewise, the median survival of 26 nasal-type NK/T cell
lymphoma patients was only 7.4 months (95% CI, 0.1, 16.9) in
our series. The overall response to the primary anthracycline-
based chemotherapy in 17 patients was poor (overall CR rate
35.3%, 95% C.I. 12.6, 58.0). We have previously reported that three
or four cycles of CHOP followed by IFRT was not satisfactory for
treating patients with localised nasal NK/T cell lymphoma due to
low CR rate (six of 15 patients, 40%, Kim et al, 2001). Owing to the
limitations of a retrospective study and the small number of
patients in the series, conclusions on the optimal treatment or
pattern of failure cannot be made. In localised disease, all three
relapsed patients showed local failure while two live patients in
remission had received IFRT following four cycles of CHOP. This
may suggest a possible role of IFRT for local disease control in
nasal-type NK/T cell lymphoma, although IFRT alone has shown to
be unsatisfactory due to frequent systemic failures (Kim et al,
2000).
One possible explanation for the resistance to the standard
chemotherapy would be a high expression of multidrug resistance
(P-glycoprotein positive) phenotype in NK/T cell lymphoma
patients. One study reported that an immunohistochemical
staining against MDR in 28 NK/T cell lymphoma patients with
primary cutaneous involvement revealed 78.6% MDR positivity,
although its clinical correlation is yet to be defined (Mraz-
Gernhard et al, 2001).
Considering the poor outcome of standard treatments, few
groups designed an innovative therapy. The Chinese group
Table 3 Prognostic factors
OS (P-value)
Variables Univariate analysis Multivariate analysis
Age (460) 0.0283 0.0261
Sex 0.7947 0.4681
PS (ECOG 2–4) 0.0004 0.0031
B symptom 0.0202 0.6352
LDH 0.0822 0.3851
IPI 0.0018 0.2692
BM (+) 0.0161 0.2121
EBV (+) 0.7008 0.7310
Stage (disseminated) 0.0003 0.0017
Time (months)
100 80 60 40 20 0
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P = 0.0003
Localised: median OS, 19.2 months (95% CI, 0, 46.5) 
Disseminated: median OS 1.3 months (95% CI,0, 4.3)
Localised 
Disseminated 
Figure 2 Overall survival curve according to stage.
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type NK/T cell lymphoma with four courses of l-asparaginase
combined with vincristine and prednisone as an induction therapy
followed by six courses of CHOP as a consolidation treatment
(Obama et al, 2003). Lee et al (2004) recently administered a
combination chemotherapy of ifosfamide, methotrexate and
etoposide in six extranasal NK/T cell lymphoma patients and
reported a 20% CR rate.
In conclusion, we suggest that the anthracycline-based chemo-
therapy should not be used as a primary treatment for localised or
advanced nasal-type NK/T cell lymphoma. Furthermore, because
of the tendency of local failure for localised disease, the addition of
radiation therapy to chemotherapy should be incorporated in a
prospective trial. Nasal-type, NK/T cell lymphoma is a highly
aggressive disease and the exploration for highly active drug is
crucial to improve survival.
REFERENCES
Bekkenk MW, Jansen PM, Meijer CJ, Willemze R (2004) CD56+ hematological
neoplasms presenting in the skin: a retrospective analysis of 23 new cases
and 130 cases from the literature. Ann Oncol 15: 1097–1108
Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau
WH (1997) Nonnasal lymphoma expressing the natural killer cell marker
CD56: a clinicopathologic study of 49 cases of an uncommon aggressive
neoplasm. Blood 89: 4501–4513
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM,
Lister TA, Vose J, Grillo-Lo ´pez A, Hagenbeek A, Cabanillas F,
Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO,
Carter W, Hoppe R, Canellos GP (1999) Report of an international
workshop to standardize response criteria for non-Hodgkin’s lympho-
mas. J Clin Oncol 17: 1244–1253
Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW (2002) Early stage
nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the
effect of treatment modality. Int J Radiat Oncol Biol Phys 54: 182–190
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK,
Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization
Classification of neoplastic diseases of the hematopoietic and lymphoid
tissues: report of the Clinical Advisory Committee Meeting – Airlie
House, Virginia, November 1997. J Clin Oncol 17: 3835–3849
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De
Wolf-Peeters C, Falini B, Gatter KC (1994) A revised European–
American classification of lymphoid neoplasm: a proposal from the
International Lymphomas Study Group. Blood 84: 1361–1392
Hirakawa S, Kuyama M, Takahashi S, Yamasaki O, Kanzaki H, Teshima T,
Harada M, Ma Y, Kawabata T, Yoshino T, Arata J (1999) Nasal and nasal-
type natural killer/T-cell lymphoma. J Am Acad Dermatol 40: 268–272
Jaffe ES (1996) Classification of natural killer (NK) cell and NK-like T-cell
malignancies. Blood 87: 1207–1210
Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC (1996) Report
of the workshop on nasal and related extranodal angiocentric T/natural
killer cell lymphomas: definitions, differential diagnosis and epidemiol-
ogy. Am J Surg Pathol 20: 103–111
Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M (1999) Extranodal
peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 111(Suppl 1):
S46–S55
Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM
(1992) Neural cell adhesion molecule-positive peripheral T-cell lympho-
ma: a rare variant with a propensity for unusual sites of involvement.
Blood 79: 2432–2437
Kim BS, Kim TY, Kim CW, Kim JY, Heo DS, Bang YJ, Kim NK (2003)
Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated
with chemotherapy. Acta Oncol 42: 779–783
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY,
Hahn JS, Roh JK, Kim BS (2000) Angiocentric lymphoma of the head and
neck: patterns of systemic failure after radiation treatment. J Clin Oncol
18: 54–63
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG,
Kang WK, Lee HJ, Park CH, Park K (2001) CHOP followed by involved
field radiation: is it optimal for localized nasal natural killer/T-cell
lymphoma? Ann Oncol 12: 349–352
Ko YH, Cho EY, Kim JE, Lee SS, Huh JR, Chang HK, Yang WI, Kim CW,
Kim SW, Ree HJ (2004) NK and NK-like T-cell lymphoma in extranasal
sites: a comparative cllinicopathological study according to site and EBV
status. Histopathology 44: 1–10
Kobashi Y, Nakamura S, Sasajima Y, Koshikawa T, Yatabe Y, Kitoh K, Mori
S, Ueda R, Yamabe H, Suchi T (1996) Inconsistent association of
Epstein–Barr virus with CD56(NCAM)-positive angiocentric lymphoma
occurring in sites other than the upper and lower respiratory tract.
Histopathology 28: 111–120
Lee KW, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim
BK, Kim NK (2004) Efficacy of ifosfamide, methotrexate, etoposide and
prednisone (IMEP) chemotherapy in extranodal NK/T cell lymphoma,
nasal type. Proc Am Soc Clin Oncol 22: 603s (abstr 6685a)
Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, Choy D, Ho FC (1995)
Treatment outcome and prognostic factors for primary nasal lymphoma.
J Clin Oncol 13: 666–670
Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH
(2001) Natural killer/natural killer-like T-cell lymphoma, CD56+,
presenting in the skin: an increasingly recognized entity with an
aggressive course. J Clin Oncol 19: 2179–2188
Nakamura S, Suchi T, Koshikawa T, Kitoh K, Koike K, Komatsu H,
Iida S, Kagami Y, Ogura M, Katoh E (1995) Clinicopathologic study
of CD56 (NCAM) positive angiocentric lymphoma occurring in sites
other than the upper and lower respiratory tract. Am J Surg Pathol 19:
284–296
Obama K, Tara M, Niina K (2003) L-asparaginase-based induction therapy
for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78:
248–250
Peiper SC (1993) Angiocentric lymphoproliferative disorders of the
respiratory system: incrimination of Epstein–Barr virus in pathogenesis.
Blood 82: 687–690
Wong KF, Chan JKC, Ng CS, Lee KC, Tsang WYW, Cheung MMC
(1992) CD56 (NKH1)-positive hematolymphoid malignancies: an
aggressive neoplasm featuring frequent cutaneous/mucosal involvement,
cytoplasmic azurophilic granules and angiocentricity. Hum Pathol 23:
798–804
Treatment of nasal-type NK/T cell lymphoma
J Lee et al
1230
British Journal of Cancer (2005) 92(7), 1226–1230 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s